本帖最后由 老马 于 2012-1-13 21:20 编辑
- Y8 V, A4 u- v8 X5 \5 f, ~
/ a& `. v: t$ \' I% i! I$ i爱必妥和阿瓦斯丁的比较
+ _6 `: J% u) W
7 b; S2 m! o, E4 M! W1 V+ Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/% N8 g Q1 `5 R$ g
$ f9 ~5 P& T# w4 `
8 y7 u& X+ B9 U" V& d1 \& X- q2 Yhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 h) u0 g7 F( S5 A7 J+ e/ [==================================================
7 g& |6 v/ y1 ?1 dOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- A& d2 D) G# ]6 X3 K0 V; MPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' t9 D) [7 g7 R$ r: c8 H% k4 SResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ }$ I0 B/ a; ?# _9 Z/ ]9 r, U6 r
|